Y-mAbs Therapeutics Inc

Active trials

• phase2Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrowactive not recruitingn=122
• phase1Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomaterminatedn=1
• phase1GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2recruitingn=60
• phase2Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastomaterminatedn=2
• phase3131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastasesterminatedn=52
• phase1Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancerterminatedn=177
• phase1Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapycompletedn=50
• phase1Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneumterminatedn=54